Clinical Trials
44 trialsHypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Mayo Clinic
Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery
Mayo Clinic
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients
National Cancer Institute (NCI)
Hypofractionated Radiotherapy for Soft Tissue Sarcomas
University of Wisconsin, Madison
HypoRTCx-UG
Uganda Cancer Institute
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
M.D. Anderson Cancer Center
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
SOAR
University of Utah
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
University of Wisconsin, Madison
NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer
M.D. Anderson Cancer Center
A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
SWIFT RT
Washington University School of Medicine
Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors
Second Affiliated Hospital of Soochow University
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
M.D. Anderson Cancer Center
NOVEMBER
University of Utah
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Mayo Clinic
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
University of California, San Francisco
A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation
Mayo Clinic
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
Zhejiang Cancer Hospital
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Hebei Medical University Fourth Hospital
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Thomas Jefferson University
Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer
Fudan University
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Academic and Community Cancer Research United
The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities
Fujian Medical University Union Hospital
Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial
University of Washington
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
University of Washington
Hypofractionated Radiotherapy for Prostate Cancer
University Hospital, Ghent
Hypofraction
University Hospital, Ghent
PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.
Second Affiliated Hospital of Soochow University
Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)
Second Affiliated Hospital of Soochow University
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
University of Washington
Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC
The First Affiliated Hospital of Xiamen University
Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor
Sun Yat-sen University
Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer
Emory University
SINDIR
Maria Sklodowska-Curie National Research Institute of Oncology
UN-RESARC
Maria Sklodowska-Curie National Research Institute of Oncology
CTV
Zhejiang Cancer Hospital
LIPOMYX
Maria Sklodowska-Curie National Research Institute of Oncology
Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer
University of California, San Francisco
HYPOLAN
The Netherlands Cancer Institute
2-weeks of Adjuvant Radiotherapy in Patients With Breast Cancer
PIMERIndia